Unmet Needs in Multiple Myeloma Ahead of ASCO 2024

Now Viewing

EP: 1.Unmet Needs in Multiple Myeloma Ahead of ASCO 2024

EP: 2.Long-Term Follow-Up Data from MajesTEC-1 at ASCO 2024

EP: 3.MajesTEC-1 and the Value of Long-Term Follow-Up Data from ASCO 2024

EP: 4.Use of Prophylactic Tocilizumab with Teclistamab: Takeaways from ASCO 2024

EP: 5.ASCO 2024: DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, and Dexamethasone

EP: 6.Future Directions in the Management of Multiple Myeloma

Video content above is prompted by the following:

• Coming into ASCO 2024, what did you consider to be the largest unmet needs in the treatment and management of multiple myeloma (MM)?
• What are the latest trends and innovations you have observed in the treatment and management of MM leading up to and coming out of ASCO 2024?
• How does relapsed/refractory MM (RRMM), particularly after multiple lines of therapy, affect the quality of life of patients and their families?